THE DEPUTY MINISTER IN THE MINISTRY OF HEALTH AND FAMILY WELFARE AND DEPUTY MINISTER IN THE MINISTRY OF INDUSTRY (SHRI DASAI CHOW-DHARY): (a) to (c) Yes, Sir. CPWD is already engaged for the Construction of the building.

Study of MAPE

556. SHRIMATI RATAN KUMARI: Will the Minister of PETROLEUM AND CHEMICALS be pleased to state:

(a) on what basis his Ministry increased MAPE;

(b) whether any study of post manufacturing expenses was taken up before or after the commencement of DPCO, 1987;

(c) what are the actual constituents of these expenses as per the records maintained by the producers;

(d) on what basis 100 per cent increase in conversion cost and packing charges was recommended by norms committee; and

(e) who examined the recommendations of committee in his Ministry?

THE MINISTER OF PETROLEUM AND CHEMICALS AND PARLIAMENTARY AFFAIRS (SHRI SATYA PRAKASH MALAVIYA): (a) and (b) The increase in the MAPE under the Drugs (Prices Control) Order, 1987 is based on the measures announced by the Government in 1986.

(c) MAPE covers profit, trade mar gin, distribution expenses, promotional expenses, etc.

(d) and (e) The recommendations of the norms Committee were accepted by the Government keeping in view the increase in costs that had taken place after May, 1979.

BICP Recommendations for Bulk Drugs and Formulations

557. SHRIMATI RATAN KUMARI: Will the Minister of PETROLEUM AND CHEMICALS be pleased to state:

(a) what are the duties and responsiblities of the BICP in regard to prices of bulk drugs and formulations;

(b) whether it is a fact that his Ministry has found a number of anomalies in the findings of BICP;

(c) whether the anomalies have been brought to the notice of the Ministry of Industry;

(d) if so, when and if not, what are the reasons therefor; and

(e) what are the names of bulk drugs and formulations in respect of which BICP have failed to send its findings?

THE MINISTER OF PETROLEUM AND CHEMICALS AND PARLIA MENTARY AFFAIRS (SHRI SATYA PRAKASH MALAVIYA): (a) to (e) In the Pharmaceutical sector BICP conducts the cost-cum-technical studies of the bulk drugs for the purpose of price fixation. It also works out the price of formulations based on various parameters in the DPCO. BICP is a recommendatory body and the final decision on the price is taken by the Government. The Government may not accept all its recommendations based on additional information which may be available with the Government and further clarification from BICP. Of 143 bulk drugs under price control about 78 bulk drugs have been studied by the BICP so far.

Prices of drug formulations

558. SHRIMATI RATAN KUMARI: Will the Minister of PETROLEUM AND CHEMICALS be pleased to state:

(a) whether his Ministry has maintained any records relating to formu-lations for which prices have not been

reduced by the companies after the announcement of DPCO 1987; and

(b) what is the present position of che prices of Oxytetracycline, Doxy-cyclin and Insulin?

THE MINISTER OF PETROLEUM AND CHEMICALS AND PARLIAMENTARY AFFAIRS (SHRI SATYA PRAKASH MALAVIYA): (a) In terms of para 16(3) of the Drugs (Prices Control) Order, 1987, every manufacturer or importer shall give effect to the price of a bulk drug or formulation, as the case may be, as fixed by the Government from time to time, within 15 days from the receipt by such manufacturer or importer of the communication in this behalf from the Government and issue a supplementary price list in this regard to the dealers, State Drug Controllers and the Government and indicate necessary reference to such price fixation. As and when any instance of non-implementation of the reduced price comes to the notice of the Government, action as per due process of law is taken against the company concerned.

(b) No instance of non-implementation of the price fixed for formulations based on Oxytetracycline, Doxy-cychne and Insulin under DPCO, 1987 has come to the notice of the Government

Revision of prices of Isoptin and Persantin

559. SHRIMATI RATAN KUMARI: Will the Minister of PETROLEUM AND CHEMICALS be pleased to state:

(a) what was the landed cost of import of bulk drugs taken into consideration for revising the prices of Isoptin and Persantin and when were the prices revised; and

(b) what were the earlier and revised prices and the justification of increase in each case?

THE MINISTER OF PETROLEUM AND CHEMICALS AND PARLIAMENTARY AFFAIRS (SHRI SATYA PRAKASH MALAVIYA): (a) and (b) The requisite information to the extent available is given in the annexed statement. [See Appendix CLVIL, Annexure No. 14].

Air **Service between Delhi and Jorhat**

560. SHRI BHADRESWAR BURAGOHAIN: Will the Minister of CIVIL AVIATION be pleased to state:

(a) whether it is a fact that there is no direct or indirect flight from Delhi to Jorhat;

(b) if so, whether Government are contemplating to provide air service between Delhi and Jorhat when the air flights are re-scheduled next; and

(c) if not, what are the reasons therefor?

THE MINISTER OF STATE IN THE MINISTRY OF CIVIL AVIATION (SHRI HARMOHAN DHAWAN): (a) Yes, Sir.

(b) and (c) While it is not feasible to provide a direct air service between Delhi and Jorhat, the question of pro viding convenient connections between Delhi and stations in the North Eastern Region, including Jorhat, will be given due considera tions at the time of revision of the current schedules of Indian Airlines.

Setting up of **a Central University** in Assam

561. SHRI BHADRESWAR BURAGOHAIN: Will the Minister of HUMAN RESOURCE DEVELOP MENT be pleased to state:

(a) whether the State Government of Assam has offered a plot of land at Napam near Tezpur for the setting up of the proposed Central University in Assam; and

(b) if so, what are the details thereof?